Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Follow this link:
Sanofi: Information concerning the total number of voting rights and shares – November 2024
VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners’ latest research report. The publication, titled "Sirona Biochem’s TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326’s clinical trial performance, setting it apart from traditional retinoid treatments.
Read the original:
Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report
MANKATO, Minn., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Digital Utilities Ventures (OTC: DUTV), a green solutions company focused on regenerative agriculture and clean water technologies, is pleased to announce a strategic partnership with TradersQue LLC (www.TradersQue.com). The collaboration aims to leverage TradersQue’s innovative business solutions to support DUTV’s ongoing growth and expansion efforts across the Agricultural and other new markets.
See the original post:
Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives
Commitment to safety, quality, and sustainability aligns with ECCO’s rigorous certification standards Commitment to safety, quality, and sustainability aligns with ECCO’s rigorous certification standards
Read the original post:
Raw Garden Sets New Standard in Cannabis Industry by Pursuing ECCO Certification
- Transaction eliminates $11.2 million in debt, strengthening financial position -
See original here:
Serina Therapeutics Announces Sale of UniverXome Subsidiary
BOSTON, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. a biotechnology company developing next generation Antibody Drug Conjugates (“ADCs”) and Bispecific ADCs (“BsADCs), announced that it has been selected to participate in Seed Showcase, part of Biotech Showcase™ 2025.
Read more from the original source:
Radiance has been selected to Present at the 2025 Biotech Showcase™ Alongside the J.P. Morgan Healthcare Conference
Ad hoc announcement pursuant to Art. 53 LR
VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biologic Pharmamedical is proud to announce the launch of its groundbreaking line of functional beverages, featuring patented technologies designed to biohack everyday rituals for improved health, longevity, and performance. These new products are set to redefine the wellness landscape in 2025, integrating cutting-edge science into daily habits.
Go here to read the rest:
Biologic Pharmamedical Launches Innovative Functional Beverages for Health, Longevity, and Performance
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Santhera on a cashless basis, reinforcing its position as a major shareholder in the Company.
See the rest here:
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.
Follow this link:
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy